Kaushik Aditi, Gupta Vrinda, Kaushik Manish, Ankalgi Amardeep, Ashawat M S, Verma C P S, Baral Deewakar
Department of Pharmaceutical Analysis, Laureate Institute of Pharmacy, Kangra, Himachal Pradesh, India.
Department of Pharmacology, Chitkara University, Rajpura, Punjab, India.
Inflammopharmacology. 2025 Aug;33(8):4167-4180. doi: 10.1007/s10787-025-01849-0. Epub 2025 Jul 28.
The emerging pervasiveness of osteoarthritis (OA) in the general population has necessitated the exploration of the design and development of novel treatment options. The joint has been recognized as a separate entity undergoing degenerative processes, highlighting the multifaceted nature of osteoarthritis. OA is a widespread and disabling chronic joint condition, primarily affecting the elderly population. Despite incremental advances in our understanding of OA pathophysiology and the development of new treatment strategies, the long-term management of this complex disease remains a significant challenge. Emerging evidence highlights the central role of inflammatory markers progression of OA. This comprehensive review aims to synthesize the latest insights into OA disease mechanisms and explore how these advancements can be leveraged to improve clinical outcomes, while also addressing the persistent roadblocks that continue to hinder effective management. Furthermore, this review provides comprehensive insights into the novel anti-inflammatory compounds along with other developments in the field of osteoarthritis management.
骨关节炎（OA）在普通人群中日益普遍，这使得探索新型治疗方案的设计与开发成为必要。关节已被视为一个经历退行性过程的独立实体，这凸显了骨关节炎的多面性。OA是一种广泛存在且致残的慢性关节疾病，主要影响老年人群。尽管我们对OA病理生理学的理解不断进步，新的治疗策略也不断发展，但这种复杂疾病的长期管理仍然是一项重大挑战。新出现的证据凸显了炎症标志物在OA进展中的核心作用。本综述旨在综合对OA疾病机制的最新见解，探讨如何利用这些进展来改善临床结果，同时也解决持续阻碍有效管理的障碍。此外，本综述还提供了对新型抗炎化合物以及骨关节炎管理领域其他进展的全面见解。
